As the race to generate compelling clinical data to prove the concept of antigen-specific immunotherapies gains momentum, the 2nd Antigen-Specific Immune Tolerance Drug Development Summit returns to Boston in 2019 to help large pharma, biotech, and academic researchers to overcome the complexity of auto-immune mediated disorders, expand opportunities through combination strategies and undertake a more precise and antigen-specific approach to novel drug development.
KEY Features of the 2nd Antigen-Specific Immune Tolerance Drug Development Summit:
|World-Class Speaker Faculty from the Likes of GSK, Eli Lilly, ITN & FDA|
|Curated Learning Journey from Early Discovery to Clinical Development|
|An Impactful 3-Day Summit with Solution Led Case Studies from the Fields of Allergy & Autoimmunity|
|Deep-Dive into the Crucial Challenges & Critical Decision Making to Successfully Translate Promising Strategies into Effective Therapies|
|Critical Strategic Discussions Focused On Expanding Opportunities Through Combination Therapies to Address Unmet Clinical Needs|
|Intimate Networking with Key Decision-Makers from large Pharma, Biotech & Academia Through High-Quality Discussions|
Take a look at the full event guide to see why this is an event you won’t want to miss.
“This meeting will provide opportunities to network with key scientists, hear about the latest developments and state-of-the-art science in the field of immune tolerance”
Antoon Van Oosterhout
VP & Head Allergic Inflammation Discovery Performance Unit
“I look forward to participating at this summit as cross-disease and cross-discipline exchanges are critical if we are to make disease- modifying therapy a reality in type 1 diabetes”
Director- Diabetes Program
Benaroya Research Institute